Risk-based Study Execution

Our risk-based study conduct services provide a better way of identifying, visualizing, managing, and documenting trial risks that could compromise patient safety, data quality and delay the approval of Investigational Products. Underpinned by Central Statistical Monitoring, a technique that’s currently being utilized by the Food and Drug Administration (FDA) for selecting sites for inspection, our solution can lead to up to 40% reduction on site monitoring vists and SDV, while flagging risks much earlier on.

Designed to be swiftly integrated to any site monitoring models, our risk-based study conduct services will help you optimizing your CRA workforce, while flagging and tracking risks near real-time. Early detection – Early action – Early success.

Forget about huge monitoring costs and compromised study data due to quality issues. Our data analysts, supported by high-tech smart engines, will be the eyes behind you studies’ conduct to make every data point counts, so that your product can reach the market faster.